The FDA accepts BLA and grants priority review for lecanemab for treatment of early Alzheimer's disease under the accelerated approval pathway
STOCKHOLM, July 6, 2022 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that…